Canna~Fangled Abstracts Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy Exp Neurol. 2022 Dec 6;114294. doi: 10.1016/j.expneurol.2022.114294. Online ahead of print. Victoria Golub 1, Sreevidhya Ramakrishnan 2, Doodipala Samba…Freedom WaresDecember 6, 2022
Canna~Fangled Abstracts Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures Exp Neurol. 2022 Oct 7;114240. doi: 10.1016/j.expneurol.2022.114240. Online ahead of print. Doodipala Samba Reddy 1, Robert H…Freedom WaresOctober 7, 2022
Canna~Fangled Abstracts Current and future pharmacotherapy options for drug-resistant epilepsy Expert Opin Pharmacother. 2022 Sep 26. doi: 10.1080/14656566.2022.2128670. Online ahead of print. Samia Elkommos 1 2, Marco Mula 2 3…Freedom WaresSeptember 26, 2022
Canna~Fangled Abstracts Investigational small molecules in phase II clinical trials for the treatment of epilepsy: cannabidivarin, selurampanel (BGG492) and ganaxolone. Expert Opin Investig Drugs. 2018 Nov 8. doi: 10.1080/13543784.2018.1543398. Greco M1, Varriale G1, Coppola G2,…Freedom WaresNovember 8, 2018
Canna~Fangled Abstracts A Resurging Boom in New Drugs for Epilepsy and Brain Disorders. Expert Rev Clin Pharmacol. 2017 Sep 28. doi: 10.1080/17512433.2018.1386553. Younus I1, Reddy DS2. Author information…Freedom WaresSeptember 28, 2017
Canna~Fangled Abstracts Antiepileptic drugs in clinical development: differentiate or die? Curr Pharm Des. 2017 Aug 9. doi: 10.2174/1381612823666170809100524. Zaccara G1, Schmidt D2. Author information Abstract…Freedom WaresAugust 9, 2017
Canna~Fangled Abstracts Antiepileptic drugs in clinical development: differentiate or die? Curr Pharm Des. 2017 Aug 9. doi: 10.2174/1381612823666170809100524. Zaccara G1, Schmidt D2. Author information Abstract…Freedom WaresAugust 9, 2017